A new method for engineering natural killer cells could make cancer immunotherapy more efficient, scalable, and affordable, ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, ...

Phycin has been selected to receive an award through the ReGen Valley Tech Hub Call for Commercialization Resources, marking ...

Intestinal Stem Cells (ISCs) derived from a patient's own cells have garnered significant attention as a new alternative for treating intractable intestinal diseases due to their low risk of rejection ...

Cancer immunotherapy has been transformed by engineered T cells, but those bespoke treatments are slow, expensive, and out of ...

Researchers developed a way to directly reprogram human glial cells into PV interneurons without passing through a stem‑cell stage.

Pluri, Inc. ('Pluri”, the 'Company”, 'we” or 'us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its ...

New research may offer hope for endangered species Findings offer potential for regenerative medicine field Earlier study used different method for 'bipaternal' mice Jan 28 (Reuters) - Scientists in ...

The ISSCR has selected five distinguished early career scientists to serve as new Early Career Editors for Stem Cell Reports, the peer-reviewed, open access, online journal of the International ...

These factors prompted research into better and more permanent treatments for T1D. The most obvious solution: restore the natural repertoire of β cell islets. Although most recipients experienced ...